InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.022 0.01 (76%)+
Announcement
Release
21 May 2026 10:16AM
Price at Release
$0.013
Full Release
download
Summary
Avecho Biotechnology Limited has completed the treatment phase for the interim analysis cohort in its pivotal Phase III insomnia trial, involving 244 participants. The interim analysis, expected in late June 2026, aims to provide the first indication of the efficacy of Avecho's TPM-enhanced cannabidiol (CBD) capsule and support ongoing licensing discussions. The CBD TPM capsule has already received significant commercial validation, being licensed to Sandoz AG for the Australian market. The trial is designed to support registration with Australia's Therapeutic Goods Administration (TGA) and capitalize on a unique over-the-counter CBD registration pathway. Early forecasts suggest the Australian OTC CBD market could exceed US$125 million annually. Avecho's CEO, Dr. Paul Gavin, will host an investor webinar on May 25, 2026, to discuss the trial and its implications.
Key Points
  • Avecho completes treatment phase for interim analysis in Phase III insomnia trial.
  • 244 participants completed treatment, results expected by late June 2026.
  • Interim analysis to provide first efficacy indication and support licensing discussions.
  • CBD TPM capsule licensed to Sandoz AG for Australia, with significant commercial validation.
  • Phase III trial supports registration with the Therapeutic Goods Administration (TGA).
  • Avecho aims to be first to capitalize on the TGA's over-the-counter CBD registration pathway.
  • Significant market potential with over-the-counter CBD in Australia estimated at over US$125 million annually.
  • Avecho CEO Dr Paul Gavin to host an investor webinar on May 25, 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.